Clinical Trial Update: A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating subcutaneous and intravenous Velcade (bortezomib) in patients with previously treated multiple myeloma has completed enrollment and p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2011-10-04